Etude longitudinale évaluant la détérioration du gain baro-réflexe (marqueur de neuropathie autonome cardiovasculaire) et l’augmentation de la pression pulsée (marqueur de rigidité artérielle) chez le patient diabétique de type 1.PHILIPS, Jean-Christophe ; MARCHAND, Monique ; SCHEEN, André ![]() in Diabète & Métabolisme (2012), 38 Detailed reference viewed: 4 (2 ULg) Effets d’un accroissement en fruits et légumes sur neuf marqueurs de la peroxydation lipidique chez des sujets diabétiques de type 2.PAQUOT, Nicolas ; PINCEMAIL, Joël ; et alin Diabète & Métabolisme (2011), 37(suppl 1), 38 Detailed reference viewed: 33 (11 ULg) Évaluation de l’exactitude de l’estimation glycémique par un capteur de glucose enzymatique sous-cutané lors d’un exercice physique aérobie pratiqué par des patients diabétiques de type 1 sous pompe à insulineRADERMECKER, Régis ; ; et alin Diabète & Métabolisme (2008, March) Detailed reference viewed: 7 (0 ULg) L'insulinothérapie par pompe à perfusion continue d'insuline en pratique clinique: analyse rétrospective sur 508 patients-années.LEGRAND, Delphine ; SCHEEN, André ; RADERMECKER, Régis ![]() in Diabète & Métabolisme (2006), 32 Detailed reference viewed: 15 (1 ULg) Allergie systémique à l’insuline: traitement médical ou chirurgical (greffe de pancréas vascularisé).; RADERMECKER, Régis ; et alin Diabète & Métabolisme (2005), 31 Detailed reference viewed: 7 (1 ULg) Allergie systémique à l'insuline: traitement médical ou chirurgical (greffe de pancréas vascularisé)?; RADERMECKER, Régis ; et alin Diabète & Métabolisme (2005), 31 Detailed reference viewed: 9 (1 ULg) Evaluation de l'exactitude du capteur de glucose CGMS chez des patients hospitalisésRADERMECKER, Régis ; ; et alin Diabète & Métabolisme (2002), 28 Evaluation d'un capteur de glucose Detailed reference viewed: 14 (3 ULg) La diminution du gain baroréflexe dans le test de “squatting” objective bien la progression de la neuropathie autonome cardiaque: étude longitudinale pilote dans le diabète de type 1; PHILIPS, Jean-Christophe ; MARCHAND, Monique et alin Diabète & Métabolisme (2001), 27 Detailed reference viewed: 2 (0 ULg) Evaluation de la synthèse de glycogène par biopsie chimique du foie chez des sujets obèses non diabétiques et des sujets de poids normauxPAQUOT, Nicolas ; ; SCHEEN, André et alin Diabète & Métabolisme (2000), 26(suppl 1), 43 Detailed reference viewed: 13 (1 ULg) HBA1c: clinical and biological agreement for standardization of assay methode. Report by the expert of ALFEDIAM (Association de Langue française pour l'étude du diabète et des maladies métaboliques) and SFBC (Société française de Biologie clinique); ; Chapelle, Jean-Paul et alin Diabète & Métabolisme (1999), 25(3), 283-7 Glycohaemoglobin, and particularly haemoglobin A1c(HbA1c), assays have been used for many years to retrospectively evaluate the glycaemic control of diabetic patients. Cut-off values have been established ... [more ▼] Glycohaemoglobin, and particularly haemoglobin A1c(HbA1c), assays have been used for many years to retrospectively evaluate the glycaemic control of diabetic patients. Cut-off values have been established for deciding treatment modifications. The techniques used in the laboratories however exhibit varying quality, and all of them are not yet standardized. The consequence is an under-utilization of this test, especially in non-hospital practice. In this context, working groups of Société Française de Biologie Clinique (SFBC), Association de Langue Française pour l'Etude du Diabète et des Maladies Métaboliques (ALFEDIAM) and Société Française d'Endocrinologie (SFE) have met together, in order to analyze the national status, and to propose practical recommendations for implementing a standardization process on the basis of international experiences. It is recommended to exclusively express results as HbA1c percentage, using methods standardized and certified by comparison to reference methods such as those using Diabetes Control and Complications Trial (DCCT) values. Simultaneously, contacts have been established with manufacturers, and the realisation of periodic quality control surveys was encouraged. [less ▲] Detailed reference viewed: 31 (0 ULg) Effets de l’administration d’une insuline ordinaire (regular) et d’un analogue de l’insuline (lispro) sur le métabolisme postprandial du glucose chez le sujet diabétique de type 2PAQUOT, Nicolas ; ; et alin Diabète & Métabolisme (1998), 24(suppl 1), 3 Detailed reference viewed: 8 (0 ULg) Rémission complète spontanée pendant plus de 50 mois d'un diabète de type 1 typique chez une adolescente.SCHEEN, André ; LETIEXHE, Michel ; PAQUOT, Nicolas et alin Diabète & Métabolisme (1997), 23(suppl 1), 014 Detailed reference viewed: 7 (0 ULg) Comment évaluer la sécrétion insulinique en pratique?; Paquot, Nicolas ; et alin Diabète & Métabolisme (1995), 21(6), 458-64 Detailed reference viewed: 7 (0 ULg) Retinopathy, but not neuropathy, is influenced by the level of residual endogenous insulin secretion in type 2 diabetes.Bozet, Marie-Claire ; Scheen, André ; Gerard, Pascale et alin Diabète & Métabolisme (1995), 21(5), 353-9 The files of 132 patients with Type 2 diabetes were retrospectively studied to characterize the influence of metabolic control and residual insulin secretion on neuropathy and retinopathy, the two most ... [more ▼] The files of 132 patients with Type 2 diabetes were retrospectively studied to characterize the influence of metabolic control and residual insulin secretion on neuropathy and retinopathy, the two most frequent degenerative diabetic complications. Patients were classified according to their metabolic control (mean HbA1C either < or > or = 8%; reference values: 3-6%) and residual endogenous insulin secretion (fasting plasma C-peptide levels either < or > or = 0.600 nmol/l). Neuropathy was more frequent in patients with poor metabolic control (32/64 = 50%) than in those adequately controlled (17/68 = 25%; p < 0.005). In both subgroups, the level of endogenous insulin secretion did not influence the prevalence of neuropathy. Retinopathy was less effected than neuropathy by the degree of metabolic control (37.5% in the subgroup with HbA1C > or = 8% v.s. 25% in the subgroup with HbA1C < 8%; p < 0.10), but was influenced by residual insulin secretion. Indeed, in patients with inadequate metabolic control, the prevalence of retinopathy was significantly increased in those with higher endogenous insulin secretion (51.4 versus 20.6%, p < 0.02) and thus probably higher insulin resistance. Furthermore, higher systolic arterial blood pressure was observed in the subgroups with a higher prevalence of retinopathy. Such conclusions were confirmed using multivariate analysis. Thus, in Type 2 diabetes, neuropathy is essentially affected by the degree of metabolic control, whereas retinopathy is also influenced by the level of residual endogenous insulin secretion and the presence of systolic hypertension. [less ▲] Detailed reference viewed: 4 (0 ULg) Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology.; Scheen, André ; Lefebvre, Pierre ![]() in Diabète & Métabolisme (1995), 21(1), 3-25 Amylin is a 37 amino-acid peptide mainly produced by the islet beta-cell. Aggregation of amylin is partly responsible for amyloid formation. Amyloid deposits occur both extracellularly and intracellularly ... [more ▼] Amylin is a 37 amino-acid peptide mainly produced by the islet beta-cell. Aggregation of amylin is partly responsible for amyloid formation. Amyloid deposits occur both extracellularly and intracellularly and may contribute to beta-cell degeneration. Amylin is packed in beta-cell granules and cosecreted with insulin in response to the same stimuli but, unlike other beta-cell products, it is produced from specific a gene on chromosome 12. Basal, plasma amylin concentrations are around 5 pM, and increase fourfold after meals or glucose. Higher levels are found in cases of insulin resistance, obesity, gestational diabetes and in some patients with NIDDM. Low or absent levels are found in insulin-dependent diabetic patients. There are similarities between amylin and non beta-cell peptides such as calcitonin gene related peptides (CGRP). They may bind to the same receptor, determine similar post-receptor phenomena and qualitatively similar actions but with different degree of potency. The actions of amylin are multiple and mostly exerted in the regulation of fuel metabolism. In muscle, amylin opposes glycogen synthesis, activates glycogenolysis and glycolysis (increasing lactate production). Consequently, amylin increases lactate output by muscle and increases the plasma lactate concentration. In fasting conditions, this lactate may serve as a gluconeogenic substrate for the liver, contributing to replenish depleted glycogen stores and to increase glucose production. In non-fasting conditions, lactate can be transformed by liver in triglycerides. It is not clear at present whether amylin actions on the liver are direct or mediated by changes in circulating metabolites. A probably indirect effect of amylin in muscle is to decrease insulin- (or glucose)-induced glucose uptake, which may contribute to insulin resistance. Other actions include inhibition of glucose-stimulated insulin secretion and, in general, actions mimicking CGRP effects. Some of these actions are seen at supraphysiological concentrations. The physiopathological consequences of amylin deficiency, or excess are under active by investigated. [less ▲] Detailed reference viewed: 36 (1 ULg) Métabolisme hépatique du glucose après ingestion de fructose chez des sujets obèses non diabétiques et diabétiques non insulinodépendantsPAQUOT, Nicolas ; ; et alin Diabète & Métabolisme (1995), 21(suppl), Detailed reference viewed: 15 (0 ULg) Interactions entre glucocorticoïdes et sympathomimétiques et sensibilité à l'insuline chez l'hommePAQUOT, Nicolas ; ; et alin Diabète & Métabolisme (1994), 20(suppl), Detailed reference viewed: 8 (0 ULg) Le diabète de type 2 insulino-requérant: caractéristiques des patients et effets de l'insulinothérapieDUYSINX, Bernard ; SCHEEN, André ; PAQUOT, Nicolas et alin Diabète & Métabolisme (1994), 20(suppl), Detailed reference viewed: 28 (0 ULg) Comment évaluer la sensibilité à l'insuline en pratique?; Paquot, Nicolas ; et alin Diabète & Métabolisme (1994), 20(6, Nov-Dec), 556-61 Detailed reference viewed: 8 (0 ULg) Measurement of insulin sensitivity by the minimal model method using a simplified intravenous glucose tolerance test: validity and reproducibility.Duysinx, Bernard ; Scheen, André ; Gerard, Pascale et alin Diabète & Métabolisme (1994), 20(4), 425-32 This study aimed at testing whether 12 rather than 26 plasma glucose and insulin determinations can be used to calculate the indices of insulin sensitivity and of glucose effectiveness using Bergman's ... [more ▼] This study aimed at testing whether 12 rather than 26 plasma glucose and insulin determinations can be used to calculate the indices of insulin sensitivity and of glucose effectiveness using Bergman's minimal model during a simple intravenous glucose tolerance test performed without tolbutamide injection. Two intravenous glucose tolerance tests (separated by 1 week) were performed in 7 lean normal subjects and a single test was performed in 9 severely obese non-diabetic subjects. Intra-subject reproducibility of insulin sensitivity was not significantly different when 26 or 12 time-points were analyzed (CV = 16.8 +/- 3.4 versus 18.9 +/- 3.8% respectively). Compared with the insulin sensitivity of the lean subjects, that of obese subjects was significantly (P < 0.001) and similarly reduced when using 12 (2.14 +/- 0.34 versus 7.97 +/- 1.29 10(-4)min-1/mU.1-1) rather than 26 determinations (2.13 +/- 0.42 versus 6.95 +/- 1.12 10(-4) min-1/mU.1-1) respectively. Glucose effectiveness was less reproducible than insulin sensitivity and was slightly diminished by the reduction of blood samples (relative error: -9.7 +/- 4.4%; P < 0.05). Finally, glucose effectiveness tended to be slightly lower in the morbidly obese subjects than in the lean controls with both modes of calculation. In conclusion, in non-diabetic subjects, the insulin sensitivity index can be accurately measured during a simple intravenous glucose tolerance test, without tolbutamide injection and with only 12 blood samples. The possibility of performing a simplified test should contribute to increase the use of the minimal model method for estimating insulin sensitivity in clinical practice. [less ▲] Detailed reference viewed: 25 (2 ULg) |
||